Advertisement

Topics

Actelion Company Profile

23:41 EDT 19th September 2017 | BioPortfolio

Actelion Ltd, a biopharmaceutical company headquartered in Allschwil / Basel, Switzerland, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream.

Actelion focuses on the discovery, development and marketing of innovative drugs for significant unmet medical needs.

Location

Gewerbestrasse 16
Allschwil
CH 4123
Switzerland

Contact

Phone: +41 61 487 4545
Fax: +41 61 487 4500


News Articles [87 Associated News Articles listed on BioPortfolio]

Actelion’s CEO Clozel Talks Prospects of his Spin-Off Idorsia

Actelion’s spin-off Idorsia is off to a great start with a large pipeline and full pockets. CEO Jean-Paul Clozel wants it to be a second Actelion. This January, Actelion, the largest biotech in ...

Idorsia gets share of ponesimod and cadazolid revenues from Actelion

Idorsia Pharmaceuticals Ltd. entered a revenue sharing agreement with Actelion Pharmaceuticals Ltd., from which it spun off earlier this year. The arrangement relates to Actelion's ponesimod and cadaz...

Actelion Pharmaceuticals Ltd: Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD

Actelion Pharmaceuticals Ltd / Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely res...

Actelion announces changes to its executive team

Actelion Ltd announced changes to its executive team that will take effect upon the settlement of the public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH, for all publicl...

J&J starts measuring the drapes in Actelion boardroom

Actelion has detailed changes to its management team that will come into effect once the Swiss biotech…

Actelion Pharmaceuticals Ltd: Actelion veröffentlicht Update zum Phase-III-Programm IMPACT mit Cadazolid bei CDAD

Actelion Pharmaceuticals Ltd / Actelion veröffentlicht Update zum Phase-III-Programm IMPACT mit Cadazolid bei CDAD . Verarbeitet und übermittelt durch Nasdaq Corporate Solutions. Für den Inhalt der...

With Actelion’s Acquisition Done, What are the Largest European Biotechs?

With Actelion’s acquisition by J&J, there is room for a new company to take over its spot as Europe’s biggest biotech. We had a look at the new top 5. Early this year, J&J finally ...

Actelion Ltd.: Actelion veröffentlicht Update zum Phase-III-Programm IMPACT mit Cadazolid bei CDAD

ALLSCHWIL, SCHWEIZ - 08. Juni 2017 - Actelion Ltd gab heute ein Update zum Phase-III-Programm IMPACT zur Ermittlung der Wirksamkeit und Sicherheit des neuartigen Antibiotikums Cadazolid im Verglei...

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Ventavis [Actelion Pharmaceuticals US, Inc.]

These highlights do not include all the information needed to use VENTAVIS safely and effectively. See full prescribing information for VENTAVIS. VENTAVIS (iloprost) inhalation solution Initial U.S. A...

Veletri [Actelion Pharmaceuticals US, Inc.]

These highlights do not include all the information needed to use VELETRI safely and effectively. See full prescribing information for VELETRI. VELETRI (epoprostenol) for Injection Initial U.S. Approv...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401

This is an open-label, non-randomized extension to study AC-066A401. The study will assess safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a means f...

Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension

The main objective of the study is to explore the effects of ERA - at different dose strengths - on the efficacy, safety and tolerability in subjects with essential hypertension

Companies [4 Associated Companies listed on BioPortfolio]

Actelion Pharmaceuticals Ltd

Actelion aims to discover or in-license and develop a steady stream of new products as revenue sources, based on first-in class small molecule compounds. In doing so, Actelion is focussing on innovati...

Actelion Pharmaceuticals US, Inc.

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer® (bosentan), an orally available dual endothelin receptor a...

Actelion

Actelion Ltd, a biopharmaceutical company headquartered in Allschwil / Basel, Switzerland, is a leading player in innovative science related to the endothelium - the single layer of cells separating e...

Actelion Ltd

Dr. McLaughlin is currently the professor of medicine and director of the Pulmonary Hypertension Program in the Division of Cardiovascular Medicine at the University of Michigan in Ann Arbor, Michigan...

More Information about "Actelion" on BioPortfolio

We have published hundreds of Actelion news stories on BioPortfolio along with dozens of Actelion Clinical Trials and PubMed Articles about Actelion for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Actelion Companies in our database. You can also find out about relevant Actelion Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record